Advertisement

What are the Overall Strategies for Post-Thrombolytic Care That Include Use of Angioplasty?

  • C. Pepine
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 100)

Abstract

The approach to the treatment of patients with acute myocardial infarction has changed markedly over the past several years. These changes have centered on the initial management of patients with evolving myocardial infarction. The major focus of treatment now includes widespread use of thrombolytic agents. This new approach has important implications for overall strategies in the management of patients with myocardial infarction. The purpose of this paper is to address strategies for post-thrombolytic care that use mechanical recanalization in an attempt to enhance the outcome of thrombolysis alone.

Keywords

Acute Myocardial Infarction Thrombolytic Therapy Thrombolytic Agent Anisoylated Plasminogen Streptokinase Activator Complex Recurrent Ischemic Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kirchen BJ, et al. Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. Am J Cardiol 1987;59:513–515.CrossRefGoogle Scholar
  2. 2.
    Mueller HS, et al., The TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987;10:479–490.PubMedCrossRefGoogle Scholar
  3. 3.
    AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial (In press).Google Scholar
  4. 4.
    Kennedy JW. Streptokinase for the treatment of acute myocardial infarction: a brief review of randomized trials. J Am Coll Cardiol 1987;10:28B–32B.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson JL, et al. Multicenter Reperfusion Trial of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) in Acute Myocardial Infarction: Controlled comparison with Intracoronary Streptokinase. J Am Coll Cardiol 1988;11:1153–1163.PubMedCrossRefGoogle Scholar
  6. 6.
    Sheehan FH, et al. The effect of intravenous thrombolytic therapy on left ventricular function and Streptokinase from Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987;75:817–829.PubMedCrossRefGoogle Scholar
  7. 7.
    Chesebro JH, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142–154.PubMedCrossRefGoogle Scholar
  8. 8.
    Gruppo Italiano per lo Studio della Streptochinasi Nell’Infarto Miocardica (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987;2:871–874.Google Scholar
  9. 9.
    Guerci AD, et al. A randomized trial of intravenous tissue plasminogen activator for acute infarction with subsequent randomization to elective angioplasty. N Engl J Med 1987;317:1613–1618.PubMedCrossRefGoogle Scholar
  10. 10.
    Pepine CJ, et al. Percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am Heart J 1984;107:820–822.PubMedCrossRefGoogle Scholar
  11. 11.
    Rothbaum DA, et al. Emergency PTCA in acute myocardial infarction: a 3 year experience. J Am Coll Cardiol 1987;10:264.PubMedCrossRefGoogle Scholar
  12. 12.
    Topol EJ, et al., and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581–588.PubMedCrossRefGoogle Scholar
  13. 13.
    Simoons ML, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197–203.PubMedCrossRefGoogle Scholar
  14. 14.
    Stack RS, et al. Survival and cardiac event rates in the first year following emergency angioplasty for acute myocardial infarction. J Am Coll Cardiol 1988;11:1141–1149.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Neill W, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812.PubMedCrossRefGoogle Scholar
  16. 16.
    Topol EJ, et al. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in acute myocardial infarction. Circulation 1987;75:420–428.PubMedCrossRefGoogle Scholar
  17. 17.
    Fung AY, et al. Myocardial salvage by coronary angioplasty following thrombolytic failure in acute myocardial infarction. Am J Cardiol 1986;58:686–691.PubMedCrossRefGoogle Scholar
  18. 18.
    Holland K, et al. Emergency coronary angioplasty therapy for elderly patients with acute myocardial infarction: cautionary results (abstr). J Am Coll Cardiol 1987;9:232A.Google Scholar
  19. 19.
    TIMI Operations Committee. Announcement of protocol change in Thrombolysis in Myocardial Infarction Trial (Letter to Editor). J Am Coll Cardiol 1987;9:467.Google Scholar
  20. 20.
    TIMI Operations Committee. Update from the Thrombolysis in Myocardial Infarction Trial (Letter to Editor). J Am Coll Cardiol 1987;10:970.CrossRefGoogle Scholar
  21. 21.
    Fitzgerald DJ, et al. Platelet activation by streptokinase: role of plasminogen (abstr). Circulation 1987;76:IV–153.CrossRefGoogle Scholar
  22. 22.
    Eisenberg PR, et al. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527–529.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee CD, et al. The activation of human coagulation factor V by plasmin (abstr). Blood 1987;70:389a.Google Scholar
  24. 24.
    Sobel M, et al. Platelet activation enhances heparin binding (abstr). Blood 1987;70:361a.Google Scholar
  25. 25.
    Ohlstein EH, et al. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregatability in the rabbit. Thrombosis Research 1987;45:575–585.CrossRefGoogle Scholar
  26. 26.
    Shebuski RJ. Effect of thromboxane A2 (TXA) receptor antagonist (TRA) alone and in combination with a thromboxane synthetase inhibitor (TSI) on cyclic flow reduction (CFRs) in stenosed coronary arteries (abstr). Circulation 1987;76:IV–101.Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • C. Pepine
    • 1
  1. 1.Division of CardiologyUniversity of FloridaGainesvilleUSA

Personalised recommendations